Does Blue Cross Blue Shield of Massachusetts Cover Jardiance?

Blue Cross Blue Shield of Massachusetts (BCBSMA), like nearly every major commercial and Medicare Advantage insurer, includes Jardiance (empagliflozin) on its drug formularies. That much is close to certain because Jardiance has FDA approval across three separate indications backed by large cardiovascular and kidney outcome trials, which gives insurers strong clinical grounds to cover it. What is not certain, and what this page cannot answer for you, is the exact tier, copay, and prior authorization pathway on your specific BCBSMA plan. Those details are set by each plan's pharmacy and therapeutics committee, change at least annually, and were not available in any BCBSMA-published document at the time this page was written.

The useful question is not "does BCBSMA cover Jardiance" but "which of my plan's specific rules do I need to confirm before I fill this prescription, and where do I confirm them." The rest of this page separates what is established at the federal and clinical level from what is plan-specific and requires direct verification.

What Jardiance is

Jardiance is the brand name for empagliflozin, an oral SGLT2 inhibitor (sodium-glucose cotransporter-2 inhibitor) originally developed by Boehringer Ingelheim and co-marketed with Eli Lilly. It is FDA-approved for type 2 diabetes, for heart failure across the ejection fraction spectrum, and for chronic kidney disease at risk of progression. It is a distinct molecule from GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound), and from other SGLT2 inhibitors such as dapagliflozin (Farxiga) or canagliflozin (Invokana). Confirm which drug and dose your clinician has prescribed before comparing coverage, since formulary tiers can differ between drugs in the same class.

What is established versus what varies by plan

Established, and unlikely to differ much across insurers or over time:

• The FDA-approved indications for empagliflozin (type 2 diabetes, heart failure with reduced or preserved ejection fraction, and chronic kidney disease at risk of progression). Confirm current label language directly with the FDA's prescribing information for Jardiance, since label revisions occur periodically.
• SGLT2 inhibitors are recommended in diabetes and cardiology guideline documents for patients with established cardiovascular disease, heart failure, or chronic kidney disease, independent of glucose control status. This is guideline-level evidence, not a BCBSMA-specific policy, and it is the argument prescribers typically use in appeals.
• Insurers generally use tiered commercial formularies (generic, preferred brand, non-preferred brand, specialty) and require prior authorization or step therapy for newer brand-name drugs when a cheaper first-line option like metformin exists. This is standard pharmacy benefit design, not something specific to BCBSMA.
• Medicare Part D plans, including Medicare Advantage prescription drug plans, are subject to the CMS Inflation Reduction Act provisions capping total annual out-of-pocket Part D drug spending, a change that took effect for the 2025 plan year. See the CMS Inflation Reduction Act and Medicare page for current details, since implementation specifics can be updated by CMS.

Plan-specific and date-sensitive, not verifiable from public sources at the time of writing:

• Which formulary tier BCBSMA places Jardiance on for your specific plan (this can differ between HMO Blue, PPO Blue, and employer-customized plans, and between commercial and Medicare Advantage products).
• Your exact copay or coinsurance amount.
• Whether your plan requires step therapy through metformin, and what counts as a qualifying trial or documented contraindication.
• Prior authorization turnaround times and appeal deadlines for your plan.
• Whether a preferred SGLT2 inhibitor other than Jardiance is required first.

No BCBSMA-published formulary document, provider policy bulletin, or member handbook was available in the source material for this article, so none of the tier, copay, or turnaround-time figures that commonly circulate for "BCBSMA and Jardiance" should be treated as current or plan-accurate without direct confirmation. The most reliable way to get an accurate answer is to look up your own plan's formulary on BCBSMA's member portal, call the number on your insurance card, or ask your pharmacy to run a test claim.

How prior authorization and step therapy typically work for this drug class

Insurers commonly require documentation before approving a newer SGLT2 inhibitor: a confirmed type 2 diabetes diagnosis, recent HbA1c, and evidence that the patient has tried or cannot tolerate metformin, unless metformin is contraindicated. Some plans also check kidney function against the drug's labeled eGFR cutoffs before approving therapy, since empagliflozin's label specifies renal function thresholds for initiation.

For patients with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, prescribers often ask insurers to waive the metformin step therapy requirement by citing guideline recommendations that favor SGLT2 inhibitor use in these populations regardless of glucose control. Whether BCBSMA grants this waiver on a given plan, and how quickly, is a plan-level policy question that requires checking the specific plan's medical or pharmacy policy document, not a fact this article can state reliably.

If a prior authorization is denied, BCBSMA members generally have access to an internal appeal process followed by an external review option through the Massachusetts Office of Patient Protection, which handles independent external reviews of health plan denials for state-regulated plans. Self-funded employer plans are regulated under federal ERISA rules instead, so the appeal path can differ depending on how your specific plan is funded, which is itself a detail worth confirming with your benefits administrator.

What Jardiance is likely to cost, and what is not knowable in general

Out-of-pocket cost for a brand-name drug like Jardiance depends on three things that are specific to your plan and cannot be generalized: the formulary tier, whether you have met your deductible, and whether a manufacturer savings program applies.

Boehringer Ingelheim offers a manufacturer copay savings card for commercially insured patients, which can lower the out-of-pocket cost for eligible patients. Check the current eligibility rules and savings amount directly on that page, since manufacturer copay programs are adjusted periodically and cannot legally be used with Medicare, Medicaid, or other federal insurance programs.

For BCBSMA Medicare Advantage members, the CMS-mandated $2,000 annual cap on out-of-pocket Part D drug costs, effective for the 2025 plan year, applies across Part D plans nationally, including Blue Medicare Rx offerings. Members who take multiple brand-name drugs, including insulin, may reach that cap and pay nothing further for covered Part D drugs for the rest of the calendar year. Confirm current-year cap figures directly with CMS, since these figures are indexed and updated.

Wholesale acquisition cost, cash price, and specific commercial copay ranges for Jardiance change over time and were not confirmed against a current, dated source for this article. Ask your pharmacy for a real-time price quote rather than relying on a fixed number found online.

The clinical evidence behind guideline support for this drug class

Jardiance's formulary presence across most insurers is easier to understand in light of its trial evidence. A large cardiovascular outcomes trial in patients with type 2 diabetes and established cardiovascular disease reported a reduction in cardiovascular death with empagliflozin compared with placebo. Subsequent trials extended the evidence to heart failure with reduced ejection fraction, heart failure with preserved ejection fraction, and chronic kidney disease, and the FDA expanded Jardiance's approved indications accordingly over several years. The exact effect sizes and confidence intervals from these trials are reported in the original New England Journal of Medicine publications; readers or prescribers who need to cite specific numbers (hazard ratios, absolute risk reductions) in an appeal letter should pull them directly from the primary trial publication rather than from secondhand summaries, since figures are easy to transcribe incorrectly.

Diabetes and cardiology guideline bodies have incorporated this evidence into treatment recommendations favoring SGLT2 inhibitors for patients with these comorbidities. Guideline recommendations are a distinct evidentiary category from insurer policy: a guideline stating that a drug is recommended does not obligate a specific insurer to waive prior authorization, though it does strengthen the clinical argument during an appeal.

Coverage for heart failure and kidney disease indications

Because Jardiance carries separate FDA approvals for heart failure and for chronic kidney disease at risk of progression, prior authorization criteria for those indications typically differ from the diabetes-focused criteria. Plans commonly ask for documentation of heart failure symptom class and prior use of other guideline-directed heart failure therapies, or for kidney function and albuminuria values consistent with the drug's CKD indication. The specific eGFR and urine albumin-to-creatinine ratio thresholds a plan requires should be checked against that plan's current medical policy rather than assumed, since insurers sometimes set stricter internal criteria than the FDA label itself.

Jardiance is not FDA-approved for type 1 diabetes or for weight loss, and prior authorization requests for those uses are unlikely to be approved by any major insurer on clinical policy grounds, independent of BCBSMA specifically.

Comparing Jardiance to other SGLT2 inhibitors on a formulary

Insurers frequently place more than one SGLT2 inhibitor on their formulary and use tier placement to steer prescribing toward whichever drug the plan has negotiated better rebates on. Dapagliflozin (Farxiga) and canagliflozin (Invokana) are the main alternatives; ertugliflozin (Steglatro) was withdrawn from the US market by its manufacturer in 2023. Canagliflozin carries a labeled warning regarding lower-limb amputation risk that was identified in its own outcomes trial, a signal not seen in empagliflozin's or dapagliflozin's outcome trials, which is a clinically relevant difference to raise with a prescriber if a plan tries to substitute drugs within the class. Combination products containing empagliflozin (with metformin, or with linagliptin) typically sit on a different, often higher, formulary tier than the components filled separately, so ask a pharmacist to compare both options for total cost.

No generic version of empagliflozin was available in the United States as of this writing; Jardiance's US patents were understood to extend for several more years. When a generic becomes available, insurers typically move it to a lower formulary tier with fewer restrictions, following the pattern seen in other drug classes after patent expiration, though the exact timing for empagliflozin specifically should be checked against current FDA generic drug approval records closer to the relevant date.

Verification checklist: what you can trust today versus what you must confirm

Use this list before assuming any specific coverage detail applies to you. The left column rarely changes and can be checked once. The right column changes at least annually and must be reconfirmed at the start of every plan year or whenever your prescription is filled.

If a claim you read elsewhere about BCBSMA and Jardiance falls in the right-hand category and is not dated to the current plan year, treat it as unverified until you confirm it directly with BCBSMA or your pharmacy.

When to involve your prescriber or seek urgent care

Coverage delays should not lead to stopping a prescribed SGLT2 inhibitor abruptly without medical guidance, particularly for patients taking it for heart failure or kidney disease rather than glucose control alone. Contact your prescriber if a prior authorization delay is likely to interrupt therapy, and seek urgent medical attention for symptoms such as signs of diabetic ketoacidosis (nausea, vomiting, abdominal pain, unusual fatigue, difficulty breathing), which can occur with SGLT2 inhibitors even when blood glucose is not markedly elevated, or for worsening heart failure symptoms such as sudden weight gain, swelling, or shortness of breath.